Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50–59 years at increased risk of severe RSV disease and those aged ≥60 years

February 4, 2026Expert Review of VaccinesOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the cost-effectiveness of the RSVPreF3 vaccine in adults at risk for severe RSV disease.
Conducted a cost-effectiveness analysis in adults aged 50-59 and those 60 and older.
Included health outcomes related to RSV vaccination in the analysis.
Assessed economic factors such as vaccine cost and potential savings from reduced disease burden.
The RSVPreF3 vaccine is likely to offer substantial health benefits in the assessed age groups.
Implementation of the vaccine is expected to be cost-effective in reducing RSV-related healthcare costs.

Cost-effectiveness analysis evaluates RSV vaccine benefits in adults, suggesting improved health outcomes.

RSV vaccination may provide substantial health benefits and be a cost-effective intervention to reduce RSV burden in adults in Japan.

No takes yet. Share an insight, caveat, or question.

Tajima et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share